- Home
- VKTX vs LNTH Comparison
VKTX vs LNTH Comparison
Compare VKTX & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VKTX | LNTH |
|---|---|---|
| Founded | 2012 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.4B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VKTX | LNTH |
|---|---|---|
| Price | $36.24 | $66.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $87.07 | $77.33 |
| AVG Volume (30 Days) | ★ 2.9M | 1.0M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.39 |
| Revenue | N/A | ★ $1,525,933,000.00 |
| Revenue This Year | N/A | $0.01 |
| Revenue Next Year | N/A | $1.24 |
| P/E Ratio | ★ N/A | $27.84 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $18.92 | $47.25 |
| 52 Week High | $49.67 | $111.29 |
Technical Indicators
Market Signals| Indicator | VKTX | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.22 | 71.07 |
| Support Level | $36.49 | $60.15 |
| Resistance Level | $38.50 | $64.40 |
| Average True Range (ATR) | 1.85 | 2.02 |
| MACD | -0.07 | 0.72 |
| Stochastic Oscillator | 42.75 | 89.69 |
Price Performance
Historical ComparisonAbout VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.